MY134902A - Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia - Google Patents

Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Info

Publication number
MY134902A
MY134902A MYPI20015303A MYPI20015303A MY134902A MY 134902 A MY134902 A MY 134902A MY PI20015303 A MYPI20015303 A MY PI20015303A MY PI20015303 A MYPI20015303 A MY PI20015303A MY 134902 A MY134902 A MY 134902A
Authority
MY
Malaysia
Prior art keywords
treatment
familial hypercholesterolemia
rosuvastatin
heterozygous familial
heterozygous
Prior art date
Application number
MYPI20015303A
Other languages
English (en)
Inventor
Raza Ali
Hutchinson Howard Gerard
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY134902(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MY134902A publication Critical patent/MY134902A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI20015303A 2000-11-22 2001-11-20 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia MY134902A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0028429.9A GB0028429D0 (en) 2000-11-22 2000-11-22 Therapy

Publications (1)

Publication Number Publication Date
MY134902A true MY134902A (en) 2007-12-31

Family

ID=9903629

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20015303A MY134902A (en) 2000-11-22 2001-11-20 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Country Status (34)

Country Link
US (1) US6858618B2 (https=)
EP (1) EP1339409B1 (https=)
JP (2) JP5062940B2 (https=)
KR (1) KR100815042B1 (https=)
CN (1) CN1268339C (https=)
AR (1) AR031766A1 (https=)
AT (1) ATE394103T1 (https=)
AU (2) AU2002214165B9 (https=)
BG (1) BG66009B1 (https=)
BR (1) BR0115511A (https=)
CA (1) CA2429263C (https=)
CY (1) CY1110428T1 (https=)
CZ (1) CZ301583B6 (https=)
DE (1) DE60133921D1 (https=)
DK (1) DK1339409T3 (https=)
EE (1) EE05507B1 (https=)
ES (1) ES2305118T3 (https=)
GB (1) GB0028429D0 (https=)
HU (1) HUP0301380A3 (https=)
IL (2) IL155919A0 (https=)
IS (1) IS6819A (https=)
MX (1) MXPA03004336A (https=)
MY (1) MY134902A (https=)
NO (1) NO326245B1 (https=)
NZ (1) NZ525754A (https=)
PL (1) PL365386A1 (https=)
PT (1) PT1339409E (https=)
RU (1) RU2294744C2 (https=)
SI (1) SI1339409T1 (https=)
SK (1) SK6212003A3 (https=)
TW (1) TWI238720B (https=)
UA (1) UA75614C2 (https=)
WO (1) WO2002041895A1 (https=)
ZA (1) ZA200303636B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
KR20060022647A (ko) * 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
CA2537271A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005044308A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
CN1894221B (zh) * 2003-12-02 2012-08-08 特瓦制药工业有限公司 用于表征罗苏伐他汀的参照标准品
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
CA2567963A1 (en) * 2004-05-26 2005-12-08 Kgk Synergize Inc. Functional foods comprising flavonoids and tocotrienols and methods thereof
JP2007508379A (ja) * 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
US7612203B2 (en) * 2005-02-22 2009-11-03 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
KR20070062996A (ko) * 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정성 로수바스타틴 중간체
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
EP2298745B1 (en) 2008-05-27 2014-09-03 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
US8658617B2 (en) 2008-07-08 2014-02-25 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
AR092872A1 (es) 2012-09-17 2015-05-06 Madrigal Pharmaceuticals Inc Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
KR20230142523A (ko) * 2021-02-01 2023-10-11 마드리갈 파마슈티칼스, 인크. 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2051907C1 (ru) * 1989-05-22 1996-01-10 Сандос АГ Способ получения 7-замещенной гептен-6-овой кислоты
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
ATE367802T1 (de) * 2000-09-20 2007-08-15 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat

Also Published As

Publication number Publication date
CZ20031406A3 (cs) 2003-09-17
MXPA03004336A (es) 2003-08-19
NO20032292L (no) 2003-07-17
PL365386A1 (en) 2005-01-10
UA75614C2 (uk) 2006-05-15
JP5062940B2 (ja) 2012-10-31
GB0028429D0 (en) 2001-01-10
US20040072852A1 (en) 2004-04-15
US6858618B2 (en) 2005-02-22
IL155919A0 (en) 2003-12-23
EP1339409A1 (en) 2003-09-03
CN1268339C (zh) 2006-08-09
BG66009B1 (bg) 2010-10-29
PT1339409E (pt) 2008-07-07
IL155919A (en) 2009-09-01
CA2429263A1 (en) 2002-05-30
RU2294744C2 (ru) 2007-03-10
KR100815042B1 (ko) 2008-03-18
AU2002214165B9 (en) 2013-07-04
WO2002041895A1 (en) 2002-05-30
CZ301583B6 (cs) 2010-04-21
AR031766A1 (es) 2003-10-01
AU2002214165B2 (en) 2006-12-14
HUP0301380A3 (en) 2007-03-28
JP2004522714A (ja) 2004-07-29
DE60133921D1 (de) 2008-06-19
NO326245B1 (no) 2008-10-27
CN1630520A (zh) 2005-06-22
AU1416502A (en) 2002-06-03
HUP0301380A2 (hu) 2003-10-28
ES2305118T3 (es) 2008-11-01
CY1110428T1 (el) 2015-04-29
EE05507B1 (et) 2012-02-15
NZ525754A (en) 2004-10-29
SK6212003A3 (en) 2003-11-04
HK1056691A1 (en) 2004-02-27
BR0115511A (pt) 2003-12-30
IS6819A (is) 2003-05-19
KR20030048479A (ko) 2003-06-19
CA2429263C (en) 2009-03-17
TWI238720B (en) 2005-09-01
NO20032292D0 (no) 2003-05-21
BG107811A (bg) 2004-03-31
SI1339409T1 (sl) 2008-08-31
JP2010031047A (ja) 2010-02-12
DK1339409T3 (da) 2008-09-08
ZA200303636B (en) 2004-08-12
EP1339409B1 (en) 2008-05-07
ATE394103T1 (de) 2008-05-15
EE200300239A (et) 2003-08-15

Similar Documents

Publication Publication Date Title
MY134902A (en) Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
AP1449A (en) Pharmaceutical compositions comprising a hmg reductase inhibitor.
NZ525419A (en) Pharmaceutical formulations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid
ZA200205331B (en) Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid.
HUP0104828A3 (en) Crystalline bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-1,5-dihydroxyhept-6-enoic acid]calcium salt, pharmaceutical composition containing it and process for its preparation
IL175086A0 (en) Process for the manufacture of the calcium salt of rosuvastatin (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino]pyrimidin-5-yl] 3r,5s)- 3,5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
MXPA05013128A (es) Produccion mejorada de sal calcica de rosuvastatina.
MY135301A (en) Chemical process
IS2689B (is) Kristallað form bis [(E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl) amínó]pýrimídin-5-ýl](3R, 5S)-3,5-díhýdroxýhept-6-ensýru] kalsíumsalts
PL1704144T3 (pl) Sposób wytwarzania soli wapniowej kwasu (E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo](3R,5S)-3,5-dihydroksy-6-heptenowego
MY136382A (en) Use of cholesterol-lowering agent
TH88724B (th) การรักษา